Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3655-3661

  Törmäkangas, Liisa ^a   Alakärppä, Hannu ^a   David, Denise Bem ^c   Leinonen, Maija ^a   Saikku, Pekka ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; KETOLIDE; TELITHROMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; AORTA SINUS; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM DETECTION; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CHOLESTEROL DIET; CHRONIC DISEASE; CONTROLLED STUDY; DNA DETERMINATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; INTIMA; LIPID STORAGE; MOUSE; MOUSE STRAIN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; AORTA, THORACIC; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CHRONIC DISEASE; DNA; KETOLIDES; LIPID METABOLISM; LUNG; MICE; MICE, INBRED C57BL; MYOCARDIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINUS OF VALSALVA;

EID: 4644306584     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3655-3661.2004     Document Type: Article

References (57)

1. Aalto-Setala, K., K. Laitinen, L. Erkkila, M. Leinonen, M. Jauhiainen, C. Ehnholm, M. Tamminen, M. Puolakkainen, I. Penttila, and P. Saikku. 2001. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:578-584.
2. Airenne, S., H. M. Surcel, H. Alakarppa, K. Laitinen, J. Paavonen, P. Saikku, and A. Laurila. 1999. Chlamydia pneumoniae infection in human monocytes. Infect. Immun. 67:1445-1449.
3. Anderson, J. L., J. B. Muhlestein, J. Carlquist, A. Allen, S. Trehan, C. Nielson, S. Hall, J. Brady, M. Egger, B. Horne, and T. Lim. 1999. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 99:1540-1547.
4. Beatty, W. L., G. I. Byrne, and R. P. Morrison. 1993. Morphologic and antigenic characterization of interferon gamma-mediated persistent Chlamydia trachomatis infection in vitro. Proc. Natl. Acad. Sci. USA 90:3998-4002.
5. Bin, X. X., K. Wolf, T. Schaffner, and R. Malinverni. 2000. Effect of azithromycin plus rifampin versus amoxicillin alone on eradication and inflammation in the chronic course of Chlamydia pneumoniae pneumonitis in mice. Antimicrob. Agents Chemother. 44:1761-1764.
6. Blessing, E., L. A. Campbell, M. E. Rosenfeld, N. Chough, and C. C. Kuo. 2001. Chlamydia pneumoniae infection accelerates hyperlipidemia induced atherosclerotic lesion development in C57BL/6J mice. Atherosclerosis 158: 13-17.
7. Blessing, E., T. M. Lin, L. A. Campbell, M. E. Rosenfeld, D. Lloyd, and C. Kuo. 2000. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect. Immun. 68:4765-4768.
8. Bonnefoy, A., M. Guitton, C. Delachaume, P. Le Priol, and A. M. Girard. 2001. In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models. Antimicrob. Agents Chemother. 45:1688-1692.
9. Caligiuri, G., M. Rottenberg, A. Nicoletti, H. Wigzell, and G. K. Hansson. 2001. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 103:2834-2838.
10. Campbell, L. A., E. Blessing, M. Rosenfeld, T. Lin, and C. Kuo. 2000. Mouse models of C. pneumoniae infection and atherosclerosis. J. Infect. Dis. 181(Suppl. 3):S508-513.
11. Cercek, B., P. K. Shah, M. Noc, D. Zahger, U. Zeymer, S. Matetzky, G. Maurer, and P. Mahrer. 2003. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 361:809-813.
12. Chirgwin, K., P. M. Roblin, and M. R. Hammerschlag. 1989. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob. Agents Chemother. 33:1634-1635.
13. Danesh, J., R. Collins, and R. Peto. 1997. Chronic infections and coronary heart disease: is there a link? Lancet 350:430-436.
14. Douthwaite, S. 2001. Structure-activity relationships of ketolides vs. macrolides. Clin. Microbiol. Infect. 7:11-17.
15. Ekman, M. R., J. T. Grayston, R. Visakorpi, M. Kleemola, C. C. Kuo, and P. Saikku. 1993. An epidemic of infections due to Chlamydia pneumoniae in military conscripts. Clin. Infect. Dis. 17:420-425.
16. Falck, G., J. Gnarpe, and H. Gnarpe. 1996. Persistent Chlamydia pneumoniae infection in a Swedish family. Scand J. Infect. Dis. 28:271-273.
17. Fong, I. W., B. Chiu, E. Viira, D. Jang, M. W. Fong, R. Peeling, and J. B. Mahony. 1999. Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model? Clin. Diagn. Lab. Immunol. 6:891-894.
18. Fong, I. W., B. Chiu, E. Viira, D. Jang, and J. B. Mahony. 1999. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. Infect. Immun. 67:6048-6055.
19. Fong, I. W., B. Chiu, E. Viira, D. Jang, and J. B. Mahony. 2002. Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model. Antimicrob. Agents Chemother. 46:2321-2326.
20. Gieffers, J., H. Fullgraf, J. Jahn, M. Klinger, K. Dalhoff, H. A. Katus, W. Solbach, and M. Maass. 2001. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 103:351-356.
21. Gieffers, J., W. Solbach, and M. Maass. 1998. In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries. Antimicrob. Agents Chemother. 42:2762-2764.
22. Gupta, S., E. W. Leatham, D. Carrington, M. A. Mendall, J. C. Kaski, and A. J. Camm. 1997. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 96:404-407.
23. Gurfinkel, E., G. Bozovich, E. Beck, E. Testa, B. Livellara, and B. Mautner. 1999. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur. Heart J. 20:121-127.
24. Hahn, D. L., R. W. Dodge, and R. Golubjatnikov. 1991. Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA 266:225-230.
25. Hammerschlag, M. R. 2000. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J. Antimicrob. Chemother. 45:35-39.
26. Hammerschlag, M. R., K. Chirgwin, P. M. Roblin, M. Gelling, W. Dumornay, L. Mandel, P. Smith, and J. Schachter. 1992. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis. 14:178-182.
27. Hu, H., G. N. Pierce, and G. Zhong. 1999. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J. Clin. Investig. 103:747-753.
28. Ianaro, A., A. Ialenti, P. Maffia, L. Sautebin, L. Rombola, R. Carnuccio, T. luvone, F. D'Acquisto, and M. Di Rosa. 2000. Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292:156-163.
29. Kuo, C. C., and J. T. Grayston. 1988. In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob. Agents Chemother. 32:257-258.
30. Labro, M. T. 1998. Anti-inflammatory activity of macrolides: a new therapeutic potential? J. Antimicrob. Chemother. 41:37-46.
31. Laitinen, K., A. Laurila, L. Pyhala, M. Leinonen, and P. Saikku. 1997. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect. Immun. 65:4832-4835.
32. Laitinen, K., A. L. Laurila, M. Leinonen, and P. Saikku. 1996. Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment. Infect. Immun. 64:1488-1490.
33. Malinverni, R., C. C. Kuo, L. A. Campbell, and J. T. Grayston. 1995. Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J. Infect. Dis. 172:593-594.
34. Miyashita, N., H. Fukano, Y. Niki, and T. Matsushima. 2001. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J. Antimicrob. Chemother. 48:403-405.
35. Miyashita, N., H. Fukano, K. Yoshida, Y. Niki, and T. Matsushima. 2003. Chlamydia pneumoniae infection in adult patients with persistent cough. J. Med. Microbiol. 52:265-269.
36. Moazed, T. C., C. Kuo, J. T. Grayston, and L. A. Campbell. 1997. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J. Infect. Dis. 175:883-890.
37. Moazed, T. C., C. C. Kuo, J. T. Grayston, and L. A. Campbell. 1998. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J. Infect. Dis. 177:1322-1325.
38. Muhlestein, J. B., J. L. Anderson, J. F. Carlquist, K. Salunkhe, B. D. Horne, R. R. Pearson, T. J. Bunch, A. Allen, S. Trehan, and C. Nielson. 2000. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 102:1755-1760.
39. Muhlestein, J. B., J. L. Anderson, E. H. Hammond, L. Zhao, S. Trehan, E. P. Schwobe, and J. F. Carlquist 1998. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 97:633-636.
40. O'Connor, C. M., M. W. Dunne, M. A. Pfeffer, J. B. Muhlestein, L. Yao, S. Gupta, R. J. Benner, M. R. Fisher, and T. D. Cook. 2003. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 290:1459-1466.
41. Paigen, B., A. Morrow, C. Brandon, D. Mitchell, and P. Holmes. 1985. Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57:65-73.
42. Paigen, B., A. Morrow, P. A. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68:231-240.
43. Piper, K. E., M. S. Rouse, J. M. Steckelberg, W. R. Wilson, and R. Patel. 1999. Ketolide treatment of Haemophilus influenzae experimental pneumonia. Antimicrob. Agents Chemother. 43:708-710.
44. Rintamaki, S., A. Saukkoriipi, P. Salo, A. Takala, and M. Leinonen. 2002. Detection of Streptococcus pneumoniae DNA by using polymerase chain reaction and microwell hybridization with europium-labelled probes. J. Microbiol. Methods 50:313-318.
45. Roblin, P. M., and M. R. Hammerschlag. 1998. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 42:1515-1516.
46. Roblin, P. M., G. Montalban, and M. R. Hammerschlag. 1994. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob. Agents Chemother. 38:1588-1589.
47. Rothstein, N. M., T. C. Quinn, G. Madico, C. A. Gaydos, and C. J. Lowenstein. 2001. Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumoniae. J. Infect. Dis. 183:232-238.
48. Scaglione, F., and G. Rossoni. 1998. Comparative anti-inflammatory effects of roxithromycin, azithromycin and ciarithromycin. J. Antimicrob. Chemother. 41:47-50.
49. Sinisalo, J., K. Mattila, V. Valtonen, O. Anttonen, J. Juvonen, J. Melin, H. Vuorinen-Markkola, and M. S. Nieminen. 2002. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation 105:1555-1560.
50. Smieja, M., J. Mahony, A. Petrich, J. Boman, and M. Chernesky. 2002. Association of circulating Chlamydia pneumoniae DNA with cardiovascular disease: a systematic review. BMC Infect. Dis. 2:21.
51. Thadepalli, H., S. K. Chuah, L. Iskandar, and S. Gollapudi. 2002. Comparison of telithromycin, a new ketolide, with erythromycin and clarithromycin for the treatment of Haemophilus influenzae pneumonia in suckling, middle aged and senescent mice. Int. J. Antimicrob. Agents 20:180-185.
52. Törmäkangas, L., E. Saario, D. Bem David, A. Bryskier, M. Leinonen, and P. Saikku. 2004. Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J. Antimicrob. Chemother. 53:1101-1104.
53. Von Hertzen, L., H. Alakarppa, R. Koskinen, K. Liippo, H. M. Surcel, M. Leinonen, and P. Saikku. 1997. Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease. Epidemiol. Infect. 118:155-164.
54. Vuola, J. M., V. Puurula, M. Anttila, P. H. Makela, and N. Rautonen. 2000. Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge. Infect. Immun. 68:960-964.
55. Wang, S. P., and J. T. Grayston. 1970. Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test. Am. J. Ophthalmol. 70:367-374.
56. Yamaguchi, H., H. Friedman, M. Yamamoto, K. Yasuda, and Y. Yamamoto. 2003. Chlamydia pneumoniae resists antibiotics in lymphocytes. Antimicrob. Agents Chemother. 47:1972-1975.
57. Yang, Z. P., C. C. Kuo, and J. T. Grayston. 1993. A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis. Infect. Immun. 61:2037-2040.